Apyx Medical Corporation announced its preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025. The company expects total fourth quarter revenue to be in the range of $19.0 to $19.2 million, an increase of approximately 34% year-over-year. Surgical Aesthetics revenue for the quarter is anticipated to be between $16.6 and $16.8 million, up about 38% year-over-year, while OEM revenue is expected to be approximately $2.4 million, representing a 13% increase year-over-year. For the full year 2025, total revenue is projected to be in the range of $52.7 to $52.9 million, reflecting an increase of approximately 10% compared to the previous year. Surgical Aesthetics revenue for the year is expected to reach between $45.2 and $45.4 million, a 17% increase year-over-year. OEM revenue for the full year is projected at approximately $7.5 million, a decrease of 21% year-over-year. The company attributed strong fourth quarter results in part to the commercial launch of the AYON Body Contouring System™ and increased demand driven by the adoption of GLP-1 therapies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apyx Medical Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623249) on January 12, 2026, and is solely responsible for the information contained therein.
Comments